Clinical Trial Update: Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy and safety of XC221 200 mg for influenza and acute respiratory viral infections has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Viral Infection

Drugs mentioned

• XC221

Snippet

Sponsor: PHARMENTERPRISES LLC | Conditions: Influenza, Acute Respiratory Viral Infections | Phase 2 | Status: COMPLETED